trial · primary record
Zilovertamab vedotin
DLBCL
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 290 |
| Primary completion | 2027-09-24 |
| Primary endpoint | Number of participants who experienced dose-limiting toxicities (DLTs) in Part 1 |
| Registry ID | NCT05139017 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:48.859Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05139017
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Zilovertamab vedotin · compound